{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Haemophilia+B&page=2",
    "query": {
      "condition": "Haemophilia B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Haemophilia+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:48:09.111Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01090206",
      "title": "Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B",
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Vitamin D and calcium",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "MALE",
        "summary": "2 Years to 21 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2010-03",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2016-04-29",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090206"
    },
    {
      "nct_id": "NCT00956345",
      "title": "Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "nonacog beta pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2009-08",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00956345"
    },
    {
      "nct_id": "NCT05662319",
      "title": "A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Fitusiran",
          "type": "DRUG"
        },
        {
          "name": "Clotting factor concentrates (CFC) or bypassing agents (BPA)",
          "type": "DRUG"
        },
        {
          "name": "Antithrombin concentrate (ATIIIC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 91,
      "start_date": "2023-02-01",
      "completion_date": "2029-01-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 8,
      "location_summary": "Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662319"
    },
    {
      "nct_id": "NCT05164471",
      "title": "Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "verbrinacogene setparvovec",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Spur Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2021-12-06",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05164471"
    },
    {
      "nct_id": "NCT01027364",
      "title": "Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Factor IX (rFIXFc)",
          "type": "DRUG"
        },
        {
          "name": "rFIX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 123,
      "start_date": "2009-12",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027364"
    },
    {
      "nct_id": "NCT03587116",
      "title": "A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B",
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Standard of Care FIX Replacement therapy",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "18 Years to 64 Years · Male only"
      },
      "enrollment_count": 212,
      "start_date": "2018-07-26",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • San Francisco, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587116"
    },
    {
      "nct_id": "NCT00936312",
      "title": "Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 200,
      "start_date": "2008-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936312"
    },
    {
      "nct_id": "NCT01496274",
      "title": "A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rIX-FP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2012-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496274"
    },
    {
      "nct_id": "NCT01561391",
      "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "factor IX",
          "type": "OTHER"
        },
        {
          "name": "factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561391"
    },
    {
      "nct_id": "NCT02053792",
      "title": "A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rIX-FP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "Up to 70 Years · Male only"
      },
      "enrollment_count": 97,
      "start_date": "2014-02-06",
      "completion_date": "2021-06-02",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-05-22T06:48:09.111Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02053792"
    }
  ]
}